Web siteme hoÅŸ geldiniz
Web siteme hoÅŸ geldiniz
Web siteme hoÅŸ geldiniz
Web siteme hoÅŸ geldiniz
Suzan Farhang-Sardroodi, M.Sc., Ph.D.
Web siteme hoÅŸ geldiniz
Temerty
Medicine
Web siteme hoÅŸ geldiniz
Mental health is health
Suzan Farhang-Sardroodi
Department of Pharmacology and Toxicology
Temerty Faculty of Medicine, University of Toronto
I am a Research Associate in the Department of Pharmacology and Toxicology at the University of Toronto. I received my Ph.D. in Physics from the University of Zanjan (Iran) and completed an exchange semester in the Department of Applied Mathematics at the University of Waterloo (Waterloo, Ontario, Canada). I pursued postdoctoral research in quantitative oncology at the Biomathematics and Fluids Group at Toronto Metropolitan University, and in computational immunology at the Departments of Mathematics and Statistics at York University (supervised by Dr. Jane Heffernan and Dr. Iain Moyles, Toronto, Ontario, Canada), the University of Manitob (Winnipeg, Manitoba), and Université de Montréal (supervised by Dr. Morgan Craig, Montréal, Québec, Canada). My current research includes pharmacokinetics and psychiatric genetics to investigate concurrent psychiatric disorders. I am advancing my research through interdisciplinary approaches in systems pharmacology and toxicology, integrating artificial intelligence (AI) and machine learning to support translational science in mental health and the development of precision medicine.
Memberships ​​​
I am a member of:
​
​
​​
​
​​
-
Steering Committee Member, Centre for Mathematical Medicine, Fields Institute, Toronto, ON, Canada
Term: April 10, 2025 – June 30, 2028
Appointed to the Steering Committee to support interdisciplinary research and initiatives in mathematical medicine, with a focus on Systems Pharmacology & Toxicology
​
-
Affiliate Research Community Member, Acceleration Consortium (University of Toronto) — Researcher profile
Research Interests
​
Psychiatric Genetics
​
A key aspect of our work is investigating the psychiatric genetics of psychotic disorders and their comorbidities, with a focus on understanding their underlying genetic liability. By applying advanced genomic analysis techniques—including transdiagnostic approaches that examine shared genetic architecture across disorders—we aim to identify novel genetic loci and pathways that illuminate the biological mechanisms driving these conditions. This perspective recognizes that many mental health conditions share common genetic risk factors, similar symptoms, and overlapping biological mechanisms. Such insights may uncover new therapeutic targets and support the development of precision medicine interventions to address the challenges of these highly heritable and comorbid traits. An example of our current work was presented in the abstract titled Genetic Risk Factors for Concurrent Tobacco Use and Schizophrenia, at the Annual Scientific Meeting of the Pharmacogenomics Global Research Network (PGRN 2024).​
​​
Pharmacokinetics
Our work examines drug disposition and variability using quantitative, model-informed approaches. Drawing on my background in computational biology, we translate mechanistic insight into clinically relevant understanding of exposure and response.
